Support By : Li-lab
| PATHWAY_NAME | REACTOME_ID | KEGG_ID | DRUG_NAME | PUBCHEM_CID | Datasource |
|---|---|---|---|---|---|
| Vascular smooth muscle contraction | R-HSA-445355 | map04270 | clomipramine | 2801 | drug-path |
| Graft-versus-host disease | R-HSA-1643685 | map05332 | etacrynic acid | 4369270 | drug-path |
| Natural killer cell mediated cytotoxicity | R-HSA-5218921 | map04650 | etacrynic acid | 4369270 | drug-path |
| Hematopoietic cell lineage | R-HSA-173752 | map04640 | etacrynic acid | 4369270 | drug-path |
| Antigen processing and presentation | R-HSA-1236975 | map04612 | etacrynic acid | 4369270 | drug-path |
| Huntington's disease | R-HSA-1643685 | 0 | etacrynic acid | 4369270 | drug-path |
| Olfactory transduction | R-HSA-9751605 | map04740 | etacrynic acid | 4369270 | drug-path |
| Systemic lupus erythematosus | R-HSA-977105 | map05322 | etacrynic acid | 4369270 | drug-path |
| Apoptosis | R-HSA-109581 | map04210 | etacrynic acid | 4369270 | drug-path |
| Type II diabetes mellitus | R-HSA-2127377 | map04930 | etacrynic acid | 4369270 | drug-path |
| Homologous recombination | R-HSA-5685942 | map03440 | etacrynic acid | 4369270 | drug-path |
| Neuroactive ligand-receptor interaction | R-HSA-5632681 | map04080 | etacrynic acid | 4369270 | drug-path |
| Fc epsilon RI signaling pathway | R-HSA-2454202 | map04664 | etacrynic acid | 4369270 | drug-path |
| MAPK signaling pathway | R-HSA-9652817 | map04010 | etacrynic acid | 4369270 | drug-path |
| Parkinson's disease | R-HSA-1643685 | 0 | etacrynic acid | 4369270 | drug-path |
| Calcium signaling pathway | R-HSA-381753 | map04020 | etacrynic acid | 4369270 | drug-path |
| Natural killer cell mediated cytotoxicity | R-HSA-5218921 | map04650 | bupropion | 444 | drug-path |
| Alzheimer's disease | R-HSA-1643685 | 0 | bupropion | 444 | drug-path |
| Neuroactive ligand-receptor interaction | R-HSA-5632681 | map04080 | bupropion | 444 | drug-path |
| Olfactory transduction | R-HSA-9751605 | map04740 | bupropion | 444 | drug-path |